The Inherited Neuropathy Consortium (INC) RDCRC is a network of clinical investigators dedicated to developing the infrastructure necessary to evaluate therapies for patients with heritable peripheral neuropathies, collectively known as Charcot-Marie-Tooth disease (CMT). Supplemental funding from the Muscular Dystrophy Association (MDA) and Charcot Marie Tooth Association (CMTA), two of our five Patient Advocacy Groups (PAGs), has allowed the INC to expand from 6 to 20 sites. The >90 genes that cause CMT can be divided into three major groups - dominantly inherited demyelinating neuropathies (CMT1), dominantly inherited axonal neuropathies (CMT2), and recessively inherited neuropathies (CMT4). These are the groups of disorders we investigate. The INC has enrolled > 10,000 participants into our protocols including > 5,000 patients into our natural history projects. We have developed CMT specific clinical outcome assessments (COA) used to measure disability in adults and children with CMT, including both functional and patient reported outcomes (PRO). INC investigators have identified biomarkers including MRI imaging that correlate with our COA in CMT1A, the most common form of CMT. INC investigators have just been awarded a U01 award to ?Accelerate Clinical Trials in CMT (ACTCMT) for CMT1A. We have relationships with pharmaceutical and academic partners to share clinical data for trial readiness. We have had a Critical Path Innovation Meeting (CPIM) meeting with the FDA. However, we need to complete longitudinal and biomarker studies in CMT1A and the other common forms of CMT to be truly clinical trial ready for common and rare forms of CMT. The INC has also been actively involved in identifying novel genetic causes of CMT including 23 during the past five years. We have utilized GWAS to identify SIPA1L2 as the first genetic modifier for CMT1A and shown that this gene is a potential therapeutic target. We have initiated the CMT Variant Browser which promotes international sharing of genetic information on CMT and developed GENESIS software to share exome data internationally. We are now poised to expand these studies into phenotypic sharing and whole genome analysis. The INC Website has also allowed us to directly interact with > 3600 participants who constitute the INC Contact Registry who have helped us develop the CMT Health Index, a PRO measure of disease burden, among other publications. We have developed the CMT-International Database (CMT-ID), a group of national registries from around the world that use the same CMT Minimal Dataset that is used by the INC. We have successfully trained 11 young investigators who have all obtained faculty positions in fields related to CMT. We propose to extend and expand our efforts in the upcoming RDCRN cycle by (1) ensuring our COA and Biomarkers are clinical trial ready, (2) Developing and utilizing an INC Pilot/Feasibility Core, (3) Continuing to train the next generation of INC investigators, and (4) Providing information to patients, families and investigators through the INC Website.

Public Health Relevance

The Inherited Neuropathy Consortium (INC) RDCRC is a network of clinical investigators dedicated to developing the infrastructure necessary to evaluate therapies for patients with heritable peripheral neuropathies, collectively known as Charcot-Marie-Tooth disease (CMT). The >90 genes that cause CMT can be divided into three major groups - dominantly inherited demyelinating neuropathies (CMT1), dominantly inherited axonal neuropathies (CMT2), and recessively inherited neuropathies (CMT4). These are the groups of disorders we investigate. Our goals are to (1) utilize and expand our natural history data to become ?clinical trial ready? for common and rare forms of CMT, (2) identify, characterize and facilitate treatments for novel forms of CMT, (3) to train future investigators in our field, and (4) to share our data with scientists, physicians and patients in an easily accessible manner.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS065712-13
Application #
10004170
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Nuckolls, Glen H
Project Start
2009-09-30
Project End
2024-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
13
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Iowa
Department
Neurology
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Hu, Bo; McCollum, Megan; Ravi, Vignesh et al. (2018) Myelin abnormality in Charcot-Marie-Tooth type 4J recapitulates features of acquired demyelination. Ann Neurol 83:756-770
Dankwa, Lois; Richardson, Jessica; Motley, William W et al. (2018) A mutation in the heptad repeat 2 domain of MFN2 in a large CMT2A family. J Peripher Nerv Syst 23:36-39
Bai, Yunhong; Wu, Xingyao; Brennan, Kathryn M et al. (2018) Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. Ann Clin Transl Neurol 5:445-455
Rebelo, Adriana P; Saade, Dimah; Pereira, Claudia V et al. (2018) SCO2 mutations cause early-onset axonal Charcot-Marie-Tooth disease associated with cellular copper deficiency. Brain 141:662-672
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Abrams, Alexander J; Fontanesi, Flavia; Tan, Natalie B L et al. (2018) Insights into the genotype-phenotype correlation and molecular function of SLC25A46. Hum Mutat 39:1995-2007
Sandelius, Åsa; Zetterberg, Henrik; Blennow, Kaj et al. (2018) Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90:e518-e524
Lassuthova, Petra; Rebelo, Adriana P; Ravenscroft, Gianina et al. (2018) Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2. Am J Hum Genet 102:505-514
Panosyan, Francis B; Kirk, Callyn A; Marking, Devon et al. (2018) Carpal tunnel syndrome in inherited neuropathies: A retrospective survey. Muscle Nerve 57:388-394
Synofzik, Matthis; Helbig, Katherine L; Harmuth, Florian et al. (2018) De novo ITPR1 variants are a recurrent cause of early-onset ataxia, acting via loss of channel function. Eur J Hum Genet 26:1623-1634

Showing the most recent 10 out of 189 publications